Literature DB >> 28245773

Low-Density Lipoprotein Cholesterol (LDL-C): How Low?

Thomas F Whayne1.   

Abstract

Low-density lipoprotein cholesterol (LDL-C) is a well-established major cardiovascular (CV) risk factor supported by clinical evidence showing decreased atherosclerotic disease events when LDL-C is therapeutically lowered. A reasonable approach is to tailor each patient's LDL-C target level depending on the initial LDL-C level and the perceived risk. Multiple clinical entities such as the newborn, hypobetalipoproteinemia, proprotein convertase subtilisin/kexin type 9 (PCSK9) missense mutations, and an unexpected excess response to a statin or other medications, are associated with very low LDL-C levels in otherwise healthy individuals. Therefore, an issue of major interest to clinicians who buy into "lower is better" for LDL-C in the high-risk CV patient is how low can and should the LDL-C be taken? Available information is discussed and placed into context. A definite safe lowest LDL-C level cannot be specified but there appears to be support that a level as low as 20 mg/dL (0.52 mmol/l) can be justified in the highest CV risk patients with extensive atherosclerosis where plaque stabilization and regression are necessary. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Coronary artery disease; low-density lipoprotein cholesterol; peripheral arterial disease; proprotein convertase subtilisin/zzm321990kexin type 9; statins

Mesh:

Substances:

Year:  2017        PMID: 28245773     DOI: 10.2174/1570161115666170227102708

Source DB:  PubMed          Journal:  Curr Vasc Pharmacol        ISSN: 1570-1611            Impact factor:   2.719


  3 in total

1.  Analysis of longissimus muscle quality characteristics and associations with DNA methylation status in cattle.

Authors:  Zhi Chen; Shuangfeng Chu; Xin Xu; Jingyi Jiang; Wenqiang Wang; Hongliang Shen; Mingxun Li; Huimin Zhang; Yongjiang Mao; Zhangping Yang
Journal:  Genes Genomics       Date:  2019-06-29       Impact factor: 1.839

Review 2.  Genetic Risk, Adherence to a Healthy Lifestyle, and Ischemic Heart Disease.

Authors:  Thomas F Whayne; Sibu P Saha
Journal:  Curr Cardiol Rep       Date:  2019-01-10       Impact factor: 2.931

3.  Role of non-statin lipid-lowering therapy in coronary atherosclerosis regression: a meta-analysis and meta-regression.

Authors:  Walter Masson; Martin Lobo; Daniel Siniawski; Graciela Molinero; Gerardo Masson; Melina Huerín; Juan Patricio Nogueira
Journal:  Lipids Health Dis       Date:  2020-05-27       Impact factor: 3.876

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.